Polyclonal Antibodies Market Report 2026

The polyclonal antibodies market size has grown strongly in recent years. It will grow from $1.48 billion in 2025 to $1.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising demand for immunoassays, adoption of polyclonal antibodies in research, growth in biotechnology sector, increasing academic research activities, availability of animal models for antibody production.

The polyclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of precision medicine initiatives, growth in therapeutic antibody applications, technological advancements in antibody production, rising investments in diagnostics research, increasing collaborations between pharma and research institutes. Major trends in the forecast period include advanced polyclonal antibody production techniques, custom antibody development services, increasing use in diagnostic applications, growth in therapeutic research applications, expansion of academic and pharmaceutical research collaborations.

The rising incidence of cancer is expected to drive the growth of the polyclonal antibodies market in the coming years. Cancer encompasses a range of diseases marked by uncontrolled cell growth and proliferation, which can cause tissue damage and metastasis, and continues to be a leading cause of morbidity and mortality worldwide. Factors such as aging populations, lifestyle changes, and environmental exposures contribute to the increasing number of cancer cases. Polyclonal antibodies are extensively utilized in cancer research and treatment for applications such as biomarker detection, immunohistochemistry, targeted therapy, and immunotherapy, thereby enhancing diagnosis, treatment, and patient outcomes. For example, the World Health Organization reported in February 2024 that by 2050, over 35 million new cancer cases are expected, a 77% rise from approximately 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling demand in the polyclonal antibodies market.

Key players in the polyclonal antibodies market are concentrating on developing advanced solutions, including hyperimmune antibody therapies, to improve patient outcomes, minimize severe complications, and strengthen immune responses. Hyperimmune antibody therapies utilize polyclonal antibodies derived from plasma donors with high levels of neutralizing antibodies, offering targeted immune protection against viral infections. For instance, in April 2023, SAB Biotherapeutics, a US-based biotechnology company, announced positive Phase 3 trial results for SAB-185, its fully human polyclonal antibody therapy, in patients at high risk of severe COVID-19 complications. SAB-185 was designed to effectively neutralize SARS-CoV-2 and demonstrated safety and efficacy, showcasing the potential of polyclonal antibody therapies to enhance treatment outcomes for vulnerable patient groups.

In September 2024, Leinco Technologies, a US-based biotech company, acquired QED Biosciences for an undisclosed sum. This acquisition allows Leinco to expand and enhance its collection of antibodies, including both monoclonal and polyclonal, along with related research and diagnostic products and services. QED Biosciences is a US-based company specializing in polyclonal rabbit antibody production.

Major companies operating in the polyclonal antibodies market are Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., ImmonoPresice Antibodies Ltd, Fujirebio, Omega BioTek Inc., Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell.

North America was the largest region in the polyclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polyclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the polyclonal antibodies market by increasing costs of raw materials and laboratory equipment imported from major manufacturing hubs, slowing the production and supply of both primary and secondary antibodies. Research and diagnostic segments in North America, Europe, and Asia-Pacific have been particularly affected due to reliance on imports. However, tariffs have encouraged local manufacturing and investment in domestic production capabilities, which may strengthen regional supply chains and reduce dependency on imports over time.

The polyclonal antibodies market research report is one of a series of new reports that provides polyclonal antibodies market statistics, including polyclonal antibodies industry global market size, regional shares, competitors with a polyclonal antibodies market share, detailed polyclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the polyclonal antibodies industry. This polyclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polyclonal antibodies are antibodies produced by multiple B-cell clones, with each clone generating a distinct antibody molecule. Researchers in life sciences and translational medicine often use them due to their convenient handling for immunization and blood collection purposes.

The primary products derived from polyclonal antibodies include primary antibodies and secondary antibodies. A primary antibody is one of the antibodies in the polyclonal mixture that binds specifically to the target antigen. These antibodies are essential for a range of applications, such as immunohistochemistry, Western blotting, ELISA, and other immunological assays. Polyclonal antibodies are typically sourced from rabbits, goats, sheep, and other animals and are utilized in research, diagnostics, and therapy by academic institutions, research centers, pharmaceutical and biotechnology companies, diagnostic laboratories, and hospitals.

The polyclonal antibodies market consists of sales of anti-cd4 polyclonal antibodies, anti-her2 polyclonal antibodies, and anti-insulin polyclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.